Daily subcutaneous amifostine administration during irradiation of pediatric head and neck cancers

Pediatric Blood and Cancer

Volumn 48, Issue 5, 2007, Pages 579-581

  Anacak, Yavuz ^a   Kamer, Serra ^a   Haydaroglu, Ayfer ^a  

^a EGE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

Amifostine; Late effects of cancer treatment; Quality of life; Radiation oncology; Radiation therapy

Indexed keywords

AMIFOSTINE;

ADOLESCENT; ARTICLE; CANCER PATIENT; CHILDHOOD CANCER; DRUG HYPERSENSITIVITY; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEAD AND NECK CANCER; HUMAN; HYPOCALCEMIA; HYPOTENSION; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MALE; MUCOSAL DISEASE; NASOPHARYNX CANCER; NASOPHARYNX CARCINOMA; NAUSEA; PRESCHOOL CHILD; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; SCHOOL CHILD; SKIN MANIFESTATION; TREATMENT OUTCOME; VOMITING;

ADOLESCENT; AMIFOSTINE; CHILD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; RADIATION-PROTECTIVE AGENTS; RADIOTHERAPY;

EID: 33947646996     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.20740     Document Type: Article

References (21)

1. Astudillo L, Maachi B, Benyoucef A, et al. Stevens-Johnson syndrome after amifostine during radiotherapy. Int J Dermatol 2004;43:284-285.
2. Brizel D, Overgaard J. Does amifostine have a role in chemoradiation treatment? Lancet Oncol 2003;4:378-381.
3. Hensley ML, Schlichter LM, Lindley C, et al. American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectans. J Clin Oncol 1999;17: 3333-3355.
4. Koukourakis MI. Amifostine: Is there evidence of tumor protection? Semin Oncol 2003;30:18-30.
5. Thorstad WL, Haughey B, Chao KS. Pilot study of subcutaneous amifostine in patients undergoing postoperative intensity modulated radiation therapy for head and neck cancer: Preliminary data. Semin Oncol 2003;30:96-100.
6. Brizel D, Wasserman T, Henke M, et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol 2000;18:3339-3345.
7. Chao KS, Ozyigit G, Thorsdad WL. Toxicity profile if intensity-modulated radiation therapy for head and neck carcinoma and potential role of amifostine. Semin Oncol 2003;30:101-108.
8. Vacha P, Fehlauer F, Mahlmann B, et al. Randomized phase III trial of radiochemotherapy+/- amifostine in head and neck cancer. Strahlenter Onkol 2003;6:385-389.
9. Jatoi A. Agressive multimodality therapy for patients with locally advanced esophageal cancer: Is there a role for amifostine? Semin Oncol 2003;30:72-75.
10. Valkova J, Stankova J, Kavan P, et al. Effect of amifostine on reducing acute toxicity of megachemotherapy of tumors in children. Cas Lek Cesk 2002;141:316-319.
11. Adamson PC, Balis FM, Belasco IE, et al. A Phase I trial of amifostine (WR-2721) and melphalan in children with refractory cancer. Cancer Res 1995;55:4069-4072.
12. Borsi ID, Csaki C, Ferencz T, et al. Administration of Ethyol (amifostine) to a child with medulloblastoma to ameliorate hematological toxicity of high dose carboplatine. Anticancer Drugs 1996;7:121-126.
13. Bukowkski R. Cytoprotection in the treatment of pediatric cancer: Review of current strategies in adults and their application to children. Med Pediatr Oncol 1999;32:124-134.
14. Fouladi M, Stempak D, Gammon J, et al. Phase I trial of a twice-daily regimen of amifostine with ifosfamide, carboplatin, and etoposide chemotherapy in children with refractory carcinoma. Cancer 2001;92:914-923.
15. Matysiak M, Satnczak E, Wojtowitz A. Amifostine (ethyol) in the adjunctive treatment of children with acute lymphoblastic leukemia. Wiad Lek 1998;51:210-214.
16. Nowak K, Bolanowski W, Zalewska-Szewczyk B, et al. Cytoprotective effect of amifostine in children during induction therapy according to BFM-83:Report on cases. Wiad Lek 1998;51:220-226.
17. Souid AK, Fahey RC, Dubowy RL, et al. WR-2721 (amifostine) infusion in patients with Ewing's sarcoma receiving ifosfamide and cyclophosphamide with mesna: Drug and thiol levels in plasma and blood cells, a Pediatric Oncology Group Study. Cancer Chemother Pharmacol 1999;44:498-504.
18. Phan C, Paris K, Josse B, et al. Tolerance and practicality of amifostine during radiation of pediatric patients to reduce long term side effects and second malignancies. Radiother Oncol 2004;73: S1-S385.
19. Brizel DM. The role of combined radiation therapy and chemotherapy in the management of locally advanced squamous carcinoma of the had and neck. In: Perez CA, Brady LW, Halperin EC, Schmidt-Ullrich RK, editors. Principles and practice of radiation oncology. Philadelphia: Lippincott Williams-Wilkins; 2004. pp 905-917.
20. Kuttesch JF, Raney RB, Madden T, et al. Phase I evaluation of amifostine (Ethyol) in combination with ifosfamide, carboplatin and etoposide + mesna + G-CSF (ICE) in children with recurrent solid tumors. Proc Am Soc Clin Oncol 1998;17: 544a.
21. Koukourakis MI, Kyrias G, Kakolyris S, et al. Subcutaneus administration of amifostione during fractionated radiotherapy: A Randomized Phase II Study. J Clin Oncol 2000;18:2226-2233.